Nasdaq · CIK 0001411685
VTGN Vistagen Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing May 19, 2026.
Vistagen Therapeutics, Inc. (VTGN) has 23 SEC Form 4 filings on file from 13 insiders, the latest filed on May 19, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Vistagen Therapeutics, Inc., scored.
Transactions
Every row filed, 26 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | Angel S Angelov Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | - | - | 150,000 | May 19, 2026 |
| Apr 7, 2026 | Reid G. Adler Chief Legal Officer | AGrant or award Incentive Stock Option (right to buy)derivative | +18,753 | $0.00 | $0 | 18,753 | Apr 9, 2026 |
| Apr 7, 2026 | Elissa S. Cote Chief Corp Development Officer | AGrant or award Incentive Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Apr 9, 2026 |
| Apr 7, 2026 | Joshua S. Prince Chief Operating Officer | AGrant or award Incentive Stock Option (right to buy)derivative | +18,752 | $0.00 | $0 | 18,752 | Apr 9, 2026 |
| Apr 7, 2026 | Shawn Singh President and CEO | AGrant or award Incentive Stock Option (right to buy)derivative | +3,732 | $0.00 | $0 | 3,732 | Apr 9, 2026 |
| Apr 7, 2026 | Reid G. Adler Chief Legal Officer | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +56,247 | $0.00 | $0 | 56,247 | Apr 9, 2026 |
| Apr 7, 2026 | Joshua S. Prince Chief Operating Officer | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +56,248 | $0.00 | $0 | 56,248 | Apr 9, 2026 |
| Apr 7, 2026 | Shawn Singh President and CEO | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +71,268 | $0.00 | $0 | 71,268 | Apr 9, 2026 |
| Dec 31, 2025 | Joshua S. Prince Chief Operating Officer | AGrant or award Common Stock | +4,386 | $0.56 | $2,468 | 15,249 | Jan 5, 2026 |
| Dec 1, 2025 | Nick B. Tressler Chief Financial Officer | AGrant or award Common Stock (Right to Buy)derivative | +150,000 | - | - | 150,000 | Dec 4, 2025 |
| Oct 27, 2025 | Paul R Edick director | AGrant or award Stock Option (Right to Buy)derivative | +35,200 | - | - | 35,200 | Nov 4, 2025 |
| Sep 9, 2025 | Margaret M FitzPatrick director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +17,600 | $0.00 | $0 | 17,600 | Sep 11, 2025 |
| Sep 9, 2025 | Jon S Saxe director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +17,600 | $0.00 | $0 | 17,600 | Sep 11, 2025 |
| Sep 9, 2025 | Mary L. Rotunno director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +17,600 | $0.00 | $0 | 17,600 | Sep 11, 2025 |
| Sep 9, 2025 | Joanne Curley director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +17,600 | $0.00 | $0 | 17,600 | Sep 11, 2025 |
| Sep 9, 2025 | Ann Michelle Cunningham director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +17,600 | $0.00 | $0 | 17,600 | Sep 11, 2025 |
| Jun 30, 2025 | Reid G. Adler Chief Legal Officer | AGrant or award Common Stock | +7,541 | $1.70 | $13k | 24,050 | Jul 1, 2025 |
| Jun 30, 2025 | Cynthia Lynn Anderson CHIEF FINANCIAL OFFICER | AGrant or award Common Stock | +6,617 | $1.70 | $11k | 12,801 | Jul 1, 2025 |
| Jun 30, 2025 | Joshua S. Prince Chief Operating Officer | AGrant or award Common Stock | +4,882 | $1.70 | $8,299 | 10,863 | Jul 1, 2025 |
| Jun 30, 2025 | Shawn Singh President and CEO | AGrant or award Common Stock | +7,541 | $1.70 | $13k | 18,028 | Jul 1, 2025 |
| Jun 23, 2025 | Reid G. Adler Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jun 25, 2025 |
| Jun 23, 2025 | Cynthia Lynn Anderson CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jun 25, 2025 |
| Jun 23, 2025 | Elissa S. Cote Chief Corp Development Officer | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Jun 25, 2025 |
| Jun 23, 2025 | Joshua S. Prince Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jun 25, 2025 |
| Jun 23, 2025 | Shawn Singh President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Jun 25, 2025 |
| Dec 31, 2024 | Cynthia Lynn Anderson CHIEF FINANCIAL OFFICER | AGrant or award Common Stock | +2,592 | $2.51 | $6,499 | 6,184 | Jan 13, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Reid G. AdlerChief Legal Officer
- Cynthia Lynn AndersonCHIEF FINANCIAL OFFICER
- Angel S AngelovChief Medical Officer
- Elissa S. CoteChief Corp Development Officer
- Ann Michelle Cunninghamdirector
- Joanne Curleydirector
- Paul R Edickdirector
- Margaret M FitzPatrickdirector
- Joshua S. PrinceChief Operating Officer
- Mary L. Rotunnodirector
- Jon S Saxedirector
- Shawn SinghPresident and CEO
- Nick B. TresslerChief Financial Officer
Questions about VTGN
Answered from the filings on this page, as of the latest one.
Are insiders buying VTGN?
No. In the last 90 days no insider at Vistagen Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade VTGN on the open market?
No open-market trade has been scored at Vistagen Therapeutics, Inc.. The latest Form 4 on file was filed on May 19, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Vistagen Therapeutics, Inc.?
13 people have filed a Form 4 at Vistagen Therapeutics, Inc., among them Reid G. Adler (Chief Legal Officer), Cynthia Lynn Anderson (CHIEF FINANCIAL OFFICER), Angel S Angelov (Chief Medical Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.